Thrivent Financial for Lutherans Has $456,000 Stake in Relay Therapeutics, Inc. $RLAY

Thrivent Financial for Lutherans decreased its stake in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) by 47.5% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 87,418 shares of the company’s stock after selling 79,250 shares during the period. Thrivent Financial for Lutherans’ holdings in Relay Therapeutics were worth $456,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. FNY Investment Advisers LLC increased its holdings in shares of Relay Therapeutics by 100.0% during the second quarter. FNY Investment Advisers LLC now owns 10,000 shares of the company’s stock worth $34,000 after purchasing an additional 5,000 shares during the period. Quinn Opportunity Partners LLC acquired a new position in shares of Relay Therapeutics during the 2nd quarter worth $35,000. May Hill Capital LLC bought a new position in shares of Relay Therapeutics in the second quarter worth about $38,000. Focus Partners Advisor Solutions LLC bought a new position in Relay Therapeutics in the 2nd quarter valued at approximately $39,000. Finally, Quadrant Capital Group LLC boosted its holdings in shares of Relay Therapeutics by 245.1% during the 2nd quarter. Quadrant Capital Group LLC now owns 11,791 shares of the company’s stock valued at $41,000 after acquiring an additional 8,374 shares in the last quarter. 96.98% of the stock is owned by institutional investors and hedge funds.

Relay Therapeutics Price Performance

NASDAQ:RLAY opened at $9.16 on Wednesday. Relay Therapeutics, Inc. has a 1 year low of $1.77 and a 1 year high of $9.54. The business has a fifty day simple moving average of $8.20 and a two-hundred day simple moving average of $6.44. The company has a market capitalization of $1.59 billion, a P/E ratio of -5.23 and a beta of 1.59.

Wall Street Analysts Forecast Growth

RLAY has been the topic of several analyst reports. Oppenheimer raised shares of Relay Therapeutics from a “market perform” rating to an “outperform” rating and set a $14.00 price objective on the stock in a research note on Monday, January 26th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Relay Therapeutics in a research note on Friday, January 9th. Finally, Wells Fargo & Company upgraded Relay Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $6.00 to $13.00 in a report on Friday, December 12th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Relay Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $16.57.

Insider Activity

In related news, CEO Sanjiv Patel sold 43,168 shares of the stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $7.82, for a total value of $337,573.76. Following the transaction, the chief executive officer owned 661,041 shares of the company’s stock, valued at $5,169,340.62. This represents a 6.13% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Thomas Catinazzo sold 13,820 shares of Relay Therapeutics stock in a transaction that occurred on Tuesday, January 27th. The stock was sold at an average price of $7.62, for a total transaction of $105,308.40. Following the transaction, the chief financial officer directly owned 250,996 shares in the company, valued at $1,912,589.52. This trade represents a 5.22% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 93,302 shares of company stock valued at $724,355. Corporate insiders own 4.32% of the company’s stock.

About Relay Therapeutics

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.